Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Aumolertinib × aumolertinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 16 Lung Neoplasms 8 Brain Neoplasms 3 Rare Tumor 1 Radiation Pneumonitis 1 Liver Diseases 1 Digestive System Diseases 1 Aumolertinib 1

Interventions

aumolertinib 1 anlotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05778149 2023-03-21

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting

Aumolertinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡